Protara Therapeutics, INC Form 4 insider transactions

Protara Therapeutics, Inc. Director Cynthia Smith was granted 24,000 stock options with an exercise price of $3.26, vesting over one year or upon a change of control.

Protara Therapeutics, Inc. Director Barry P. Flannelly was granted 24,000 stock options with an exercise price of $3.26, vesting on the first anniversary of the grant date or upon a change of control.

Protara Therapeutics, Inc. Director Gregory Sargen was granted 24,000 stock options with an exercise price of $3.26, vesting over one year.

Protara Therapeutics, Inc. Director Luke M. Beshar was granted 24,000 stock options with an exercise price of $3.26, vesting over one year.

Protara Therapeutics, Inc. has granted 50,000 restricted stock units and options to purchase 200,000 shares of common stock to Chief Commercial Officer William Conkling, effective June 2, 2025, as part of his compensation.

Director Richard S. Levy purchased 20,000 shares of Protara Therapeutics (TARA) common stock at an average price of $3.19 on May 14, 2025.

Director Richard S. Levy of Protara Therapeutics, Inc. purchased 20,000 shares of common stock at an average price of $3.19 on May 14, 2025.

Leonardo Nicacio, Chief Medical Officer of Protara Therapeutics, reports acquisition of 50,000 shares of common stock and 150,000 stock options.

Hannah Fry, VP, Controller of Protara Therapeutics, files an amended Form 4 to correct a misreporting of securities beneficially owned following a transaction.

Jacqueline Zummo, Chief Scientific Operations Officer of Protara Therapeutics, sold 21,224 shares of common stock at an average price of $4.53 under a pre-arranged 10b5-1 trading plan.

Patrick Fabbio, CFO of Protara Therapeutics, files an amended Form 4 to correct a previously misreported amount of securities beneficially owned.

Jesse Shefferman, CEO and President of Protara Therapeutics, files an amended Form 4 to correct a previously misreported amount of securities beneficially owned.

Jacqueline Zummo, Chief Scientific Operations Officer of Protara Therapeutics, files an amendment to a previous Form 4 to correct the reported amount of securities beneficially owned.

CEO Jesse Shefferman of Protara Therapeutics acquired 65,000 shares of common stock and stock options for 387,000 shares on January 24, 2025.

Jacqueline Zummo, Chief Scientific Operations Officer of Protara Therapeutics, reports acquisition of common stock and stock options.

Hannah Fry, VP, Controller of Protara Therapeutics, reports the acquisition of 9,500 shares of common stock and 55,000 stock options.

Chief Financial Officer of Protara Therapeutics, Patrick Fabbio, reports transactions involving common stock and stock options, including the acquisition of restricted stock units and stock options.

Protara Therapeutics CEO Jesse Shefferman sold 15,469 shares of common stock on January 21, 2025, to cover income tax obligations related to vesting restricted stock units.

Patrick Fabbio, CFO of Protara Therapeutics, sold 3,061 shares of common stock on January 21, 2025, to cover income tax obligations related to a restricted stock unit award.

Hannah Fry, VP, Controller of Protara Therapeutics, reports disposing of 2,130 shares of common stock to cover income tax obligations related to vesting Restricted Stock Units.

Jacqueline Zummo, Chief Scientific Operations Officer of Protara Therapeutics, sold 6,554 shares of common stock on January 21, 2025, to cover income tax obligations related to vesting restricted stock units.

Protara Therapeutics CEO Jesse Shefferman sold 6,479 shares of common stock to cover income tax obligations related to a vesting restricted stock unit.

Jacqueline Zummo, Chief Scientific Operations Officer at Protara Therapeutics, sold 2,157 shares to cover income tax obligations related to a previously granted stock award.

Hannah Fry, VP and Controller at Protara Therapeutics, sold 394 shares of common stock to cover tax obligations related to a vested stock award.

Opaleye Management Inc. reports selling shares of Protara Therapeutics (TARA) on September 11 and 12, 2024, reducing its beneficial ownership.

Opaleye Management Inc. reports the sale of Protara Therapeutics shares held by Opaleye, L.P. and a managed account.

Protara Therapeutics CEO Jesse Shefferman reports disposition of common stock via gift.

Opaleye Management Inc. reports the sale of Protara Therapeutics shares held by Opaleye, L.P. and a managed account.

Opaleye Management Inc. reports the sale of Protara Therapeutics shares held directly and through managed accounts between July 9th and July 11th, 2024.

Opaleye Management Inc. reports the sale of Protara Therapeutics common stock, reducing its beneficial ownership.